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INTRODUCTION 
Pre Eclampsia is a multi-system disorder of unknown etiology, unique 
to pregnancy characterized by occurrence of Gestational Hypertension along 
with proteinuria after the 20th week of pregnancy in a previously normotensive 
and non-protienuric patient. Gestational Hypertension is defined as Systolic 
blood pressure of 140 mm of Hg or more and Diastolic blood pressure of 90 
mm of Hg or more on two occasions, measured at least 6 hours apart but within 
7 days. Proteinuria is defined as excretion of 0.3 g or more of protein in a 24 
hour urine sample or >1+ on dipstick in a random sample after excluding 
urinary tract infection. 
Pre Eclampsia complicates 2-8% of pregnancies. Pre Eclampsia can 
affect virtually every organ system in the body and is a major cause of maternal 
and perinatal mortality and morbidity. Pre Eclampsia, when not controlled or 
left untreated can lead to catastrophes like Eclampsia, Abruptio placenta, 
HELLP syndrome, fetal growth restriction, and intrauterine fetal death. Though 
the definitive treatment of Pre Eclampsia is termination of pregnancy, 
aggressive treatment is necessary to ameliorate the disease progression in order 
to carry on the pregnancy till adequate fetal maturity is obtained. 
 Oral anti hypertensive drugs have a major role in the management of 
Pre Eclampsia. A comparison is made here between Labetalol and the 
commonly used drug Alpha methyl dopa in the management of Pre Eclampsia. 
REVIEW OF LITERATURE 
 
Preeclampsia, a disorder with genetic and immunological components, 
occurs in approximately 3% of patients – a figure mirrored worldwide. It is 
possible that unmanaged preeclampsia could proceed to Eclampsia in a large 
proportion of cases.  
Though Eclampsia was known for centuries and attempts were made to 
find out the cause of Eclampsia, the concept of preeclampsia was discovered 
much later. It was only in the 19th century, the link between Eclampsia and 
preeclampsia was made. Rayer's landmark contribution (1839-1841) provided 
evidence for renal involvement with the observation of protein in the urine of 
pregnant, edematous women. Lever (1843), of Guy’s Hospital in London, 
published a paper on a series of cases of puerperal convulsions and reported 
finding proteinuria in Eclampsia and observed the disappearance of proteinuria 
after delivery of the child. Lever‘s work led to the belief that Eclampsia was a 
renal disease, a form of nephritis. 
Blood pressure measurements began in 1910, which was when 
preeclampsia became distinguished from Eclampsia. 
Preeclampsia and Eclampsia still account for 20% of maternal deaths 
worldwide; the current annual worldwide mortality can be estimated to be 
about 150, 000 women. The principal causes of death in the UK remain 
pulmonary complications and cerebral haemorrhage. It became clear earlier on 
in the 20th century that Eclampsia was a preventable disease and some of the 
improvement seen during this time has been due to the development of 
antenatal care with the early recognition of signs of preeclampsia and 
immediate treatment. 
Methyldopa and labetalol have for many years been primary agents used 
for control of blood pressure in pregnancy. 
Mahmoud TZ, Bjornsson S, Calder AA (1993) prospectively studied the effects 
of oral labetalol therapy in patients with moderate to severe pregnancy induced 
hypertension (PIH). The outcome variables were blood pressure control, effect 
on umbilical artery flow velocity waveforms (UAFVW) and fetal outcome. 
Forty-two patients were recruited, all had moderate to severe PIH. The mean 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) on entry were 
154 +/- 7 mmHg and 104 +/- 5 mmHg, respectively. All had significant 
proteinuria. After 1 week on labetalol therapy, 85% of patients had their blood 
pressure controlled. The reduction in both SBP and DBP was statistically 
significant. There were no significant changes in UAFVW, Resistance Index 
(RI), uric acid or platelets. The mean birth weight was 2712 +/- 609 g. No 
perinatal mortality occurred in this study. Labetalol is an effective drug in 
controlling blood pressure and does not adversely affect the UAFVW. No 
neonatal problems were attributed directly to the drug. Fetal outcome was 
satisfactory despite the 12 fetuses that were growth-retarded. Labetalol allows 
safe prolongation of pregnancies complicated by PIH. 
Richards et al., (1979) Prichard et al., (1975) established that the dual alpha- 
and beta-adrenoceptor blocking properties of labetalol in normal subjects and 
hypertensive patients lead to a similar pattern of circulatory effects. Following 
acute intravenous administration in the supine position, significant reductions 
in blood pressure occur without a fall in heart rate or cardiac output. After 
continuous oral administration to patients, small reductions in resting heart rate 
are usually found (Lund-Johansen, 1979), although individual changes are 
influenced by the degree of resting sympathetic drive. Marked reductions in 
resting heart rate after labetalol may follow intravenous administration 
(Cumming et al., 1979; Marx & Reid, 1979). Cardiac output at rest does not 
usually change much after labetalol treatment (Koch, 1976; Edwards & 
Raftery, 1976; Mehta & Cohn, 1977). 
Mabie and coworkers (1987) compared bolus intravenous labetalol with 
intravenous hydralazine in the acute treatment of severe hypertension. They 
found that labetalol had a quicker onset of action and did not result in reflex 
tachycardia. In terms of fetal effects, blood pressure reduction with labetalol 
does not result in fetal distress (Mahmoud and co-workers, 1993) unlike acute 
blood pressure reduction with hydralazine where 15% of fetuses will exhibit 
distress frequently requiring immediate cesarean section for delivery. Studies 
of uteroplacental blood flow indicate that no decrease in perfusion occurs 
despite the reduced maternal blood pressure Lunell and co-workers, 1982).   As 
with all beta-blockers, labetalol has been associated with hypoglycemia, 
bradycardia and hypotension but neonatal outcome is uniformly good and 
ACOG currently recommends labetalol as one of the first line antihypertensive 
medications for preeclampsia (ACOG, 1996). 
Labetalol has some interesting, and potentially, important non-
antihypertensive effects that may be beneficial in preeclampsia. Among these 
are an anti-platelet aggregation action, a thromboxane reducing effect (Greer 
and co-workers, 1985), and a fetal lung maturation accelerating influence 
(Micheal and co-workers, 1980). 
A prospective placebo controlled study done in Nottingham (1992) 
included 144 women (86 primigravidae) who developed PIH after 20 weeks 
gestation. They were treated with either oral labetalol up to 600 mg daily or 
placebo. Main outcomes measured included the number of days spent as an 
antenatal inpatient; the development of proteinuria; the perceived need for 
induction of labour or elective caesarean section; and gestation age at delivery. 
According to the study, Labetalol significantly lowered the blood pressure and 
reduced the incidence of proteinuria. However, neither the number of days 
spent as an antenatal inpatient, nor the perceived need for induction of delivery 
or elective caesarean section, nor the gestation age at delivery differed 
significantly between the two treatment groups. The placebo treated early-onset 
group seemed to have more patients with severe hypertension (> 150/110 
mmHg) and a greater requirement for additional antihypertensive therapy prior 
to labour than the group treated with labetalol. 
 
PRE ECLAMPSIA 
 
Preeclampsia is best described as pregnancy-specific syndrome that can 
affect virtually every organ system. Although preeclampsia is much more than 
simply gestational hypertension with proteinuria, appearance of proteinuria 
remains an important objective diagnostic criterion. Proteinuria is defined by 
24-hour urinary protein excretion exceeding 300 mg, a urinary protein: 
creatinine ratio of >= 0.3 or persistent 30 mg/dl (1+ dipstick) in random urine 
samples (Lindheimer and colleagues, 2008 a). Some women may have atypical 
preeclampsia with all aspects of the syndrome, but without hypertension or 
proteinuria, or both (Sibai and Stella, 2009). 
 
Eclampsia  
             The onset of generalized convulsions in a woman with preeclampsia 
that cannot be attributed to epilepsy or other causes is termed Eclampsia. 
Eclampsia is a preventable condition. Adequate prenatal care, early detection of 
preeclampsia and its adequate control can prevent Eclampsia; hence the need to 
treat preeclampsia aggressively. 
Indicators of Severity of Preeclampsia 
Pre Eclampsia is divided into mild and severe. Severe Pre Eclampsia is 
characterized by one or more of the following: 
1. Severe hypertension (BP 160/110 mm of Hg or more) 
2. Proteinuria (>5 g/24 hours or 3+ or more on random samples) 
3. Oliguria (<500 ml /24 hours) 
4. Elevated serum creatinine level 
5. Pulmonary oedema 
6. Thrombocytopenia (<1, 00,000 /cumm) 
7. Microangiopathic hemolysis 
8. Elevated liver enzymes 
9. Symptoms of end-organ involvement like headache, blurring of vision 
and epigastric pain 
10. Fetal growth restriction. 
11. HELLP Syndrome  
 
RISK FACTORS 
1. Age – Pre Eclampsia is more likely to occur at both extremes of age, but 
is greatest in women younger than 20 years of age. 
2. Parity – Pre Eclampsia is believed to be a disease of primigravidae. The 
incidence of pre Eclampsia in multiparous women is lower than 
primipara women. 
3. Obstetric factors – Pre Eclampsia occurs most commonly in pregnancies 
associated with a large placenta, such as multiple pregnancies, molar 
pregnancies and hydrops fetalis. Hydramnios and history of Pre 
Eclampsia in previous pregnancy are also predisposing factors. 
4. Pre existing medical disorders – like Hypertension, Gestational 
Diabetes, Renal disease, Obesity, Thrombophilias (both inherited and 
acquired) such as Antiphospholipid antibody syndrome, Factor 5 Leiden 
deficiency, Activated protein C resistance, and hyperhomocysteinaemia. 
5. Family history – Women with Pre Eclampsia are more likely to have 
family history of female relatives (mothers or sisters) affected by 
preeclampsia. 
 
AETIOPATHOGENESIS 
The exact etiology of Pre Eclampsia remains unknown. Several theories 
have been proposed over the years. As Boyd stated Pre Eclampsia remains “die 
krankheit der theorien” – the disease of theories. Any satisfactory theory 
concerning the etiology and pathogenesis of Pre Eclampsia must account for 
the observation that Pre Eclampsia is more likely to develop in women who: 
 
• Are exposed to chorionic villi for the first time 
• Are exposed to a superabundance of chorionic villi, as with twins or 
hydatidiform mole 
• Have preexisting renal or cardiovascular disease 
• Are genetically predisposed to hypertension developing during 
pregnancy. 
Thus, presence of a fetus is not a requisite for preeclampsia, although 
chorionic villi are essential. The chorionic villi need not be located within the 
uterus. Worley and associates (2008) reported a 30-percent incidence of 
preeclampsia in women with an extrauterine pregnancy exceeding 18 weeks 
gestation. 
 
Preeclampsia as a Two- Stage Disorder  
Observations that abnormal interfaces between maternal, paternal and 
fetal tissues may cause preeclampsia have led to hypothesis that the syndrome 
is a two-stage disorder. According to Redman and colleagues (2009), stage 1 is 
caused by faulty endovascular trophoblastic remodeling that downstream 
causes the stage 2 clinical syndrome. Importantly, stage 2 is susceptible to 
modification by preexisting maternal conditions that include cardiac or renal 
disease, diabetes, obesity, or hereditary influences. Thus, although such 
compartmentalization is helpful to classify the syndrome for research purposes, 
preeclampsia is clinically a continuum of worsening disease. 
 
ETIOLOGY 
Instead of being simply ‘one disease,’ preeclampsia appears to be a 
culmination of factors that likely involves a number of maternal, paternal and 
fetal factors. Those currently considered important include: 
1. Placental implantation with abnormal trophoblastic invasion of uterine 
vessels 
2. Immunological maladaptive tolerance maternal, paternal (placental) and 
fetal tissues 
3. Maternal maladaptation to cardiovascular or inflammatory changes of 
normal pregnancy 
4. Genetic factors including inherited predisposing genes as well as 
epigenetic influences. 
 Abnormal Trophoblastic Invasion  
The inciting organ in Pre Eclampsia is essentially the placenta. 
Abnormal placentation, in particular lack of dilatation of the uterine spiral 
arteries leading to placental ischaemia, seems to be the common denominator 
in the genesis of Pre Eclampsia. Optimal placental development in normal 
pregnancy involves a process of controlled trophoblastic invasion extending 
from the deciduas up to the inner third of myometrium. The endothelial lining 
and the muscular layer of the spiral arteries are disrupted and replaced by 
cytotrophoblasts, in turn converting the small caliber muscular arteries into 
large capacity low resistance spaces. The process commences around 10-12 
weeks and is completed by 18-20 weeks. In women destined to develop Pre 
Eclampsia, there is incomplete trophoblastic invasion. With such shallow 
invasion, decidual vessels, but not myometrial vessels become lined with 
endovascular trophoblasts. The deeper myometrial arteries do not lose their 
endothelial lining and musculoelastic tissue. Thus, the mean external diameter 
of these vessels is only half that of vessels in normal placentas (Fisher and 
colleagues, 2009), resulting in reduced uteroplacental blood flow.  
The ensuing placental ischaemia and hypoxia leads to an aberrant 
expression of genes which encode for certain cytokines and vasoactive 
molecules, inciting a systemic inflammatory response that contributes to the 
pathophysiology of Pre Eclampsia. Using electron microscopy, De Wolf and 
co-workers (1980) examined arteries taken from the implantation site. They 
reported that early preeclamptic changes included endothelial damage, 
insudation of plasma constituents into vessel wall, proliferation of myointimal 
cells and medial necrosis. Lipid first accumulated in myointimal cells and then 
within macrophages. Such lipid –laden cells and associated findings were 
referred to as atherosis by Hertig (1945). Typically the vessels affected by 
atherosis develop aneurismal dilatation (Khong, 1991). 
  
        
 
Immunological factors  
Loss of maternal immune tolerance to paternally derived placental and 
fetal antigens, or perhaps its dysregulation, is another theory cited to account 
for preeclampsia syndrome. The histological changes at the maternal-placental 
interface in preeclampsia are suggestive of acute graft rejection (Labrrere, 
1988). Tolerance dysregulation might also explain an increased risk when the 
paternal antigenic load is increased, that is, with two sets of paternal 
chromosomes – a “double dose”. For example, women with molar pregnancies 
have a high incidence of early-onset preeclampsia.  
Redman and colleagues (2009) recently reviewed the possible role of immune 
maladaptation in the pathophysiology of preeclampsia. Early in a pregnancy 
destined to be preeclamptic, extravillous trophoblasts express reduced amounts 
of immunosuppressive human leukocyte antigen G (HLA-G). This may 
contribute to defective placental vascularisation in stage 1. 
 
Endothelial Cell Dysfunction 
Endothelial cell dysfunction in Pre Eclampsia occurs in response to 
placental factors released secondary to ischaemic changes, setting a cascade of 
events in motion. Briefly, cytokine such as tumour necrosis factor (TNF-alpha) 
and the interleukins (IL) may contribute to the oxidative stress associated with 
preeclampsia. This is characterized by reactive oxygen species and free radicals 
that lead to formation of self propagating lipid peroxides (Manten and 
associates, 2005). These in turn generate highly toxic radicals that injure 
endothelial cells, modify their nitric oxide production, and interfere with 
prostaglandin balance. Other consequences of oxidative stress include 
activation of microvascular coagulation manifest by thrombocytopenia and 
increased capillary permeability manifest by oedema and proteinuria. 
 
Genetic factors 
Preeclampsia is a multifactorial, polygenic disorder. In their 
comprehensive review, Ward and Lindheimer (2009) cite an incident risk for 
preeclampsia of 20-40 percent for daughters of preeclamptic mothers; 11-37 
percent for sisters of preeclamptic women; and 22-47 percent in twin studies. 
From their recent review, Ward and Lindheimer (2009) found that more than 
70 genes have been studied for their possible association with preeclampsia. 
This hereditary predisposition is likely the result of hundreds of inherited 
genes. From their recent review, Ward and Lindheimer (2009) found that more 
than 70 genes have been studied for their possible association with 
preeclampsia. 
 
PATHOGENESIS 
Endothelial Cell Activation  
During the past two decades, endothelial cell activation has become the 
centerpiece in understanding the pathogenesis of preeclampsia. Unknown 
factors – likely placental in origin – are secreted into the placental circulation 
and provoke activation and dysfunction of the vascular endothelium. The 
clinical syndrome of preeclampsia is thought to result from these widespread 
endothelial cell changes. Grundmann and associates (2008) have reported that 
circulating endothelial cell – CEC – levels are significantly elevated fourfold in 
the peripheral blood of preeclamptic women. Intact endothelium has 
anticoagulant properties, and endothelial cells blunt the response of vascular 
smooth muscle to pressor agents by releasing nitric oxide. Damaged and 
activated endothelial cells may produce less nitric oxide and increase 
sensitivity to vasopressors and secrete substances that promote coagulation. 
 
Prostaglandins 
A number of prostanoids are thought to be central to the 
pathophysiology of preeclampsia syndrome. Specifically, the blunted pressor 
response in normal pregnancy is atleast partially mediated by endothelial 
prostaglandin synthesis. Compared with normal pregnancy, endothelial 
prostacyclins (PGI2) production is decreased in preeclampsia, thromboxane A2 
secretion by platelets is increased and the prostacyclin: thromboxane A2 ratio 
decreases. These actions are mediated by phospholipase A2. The net result 
favors increased sensitivity to infused angiotensin 2, and ultimately, 
vasoconstriction. Chavarria and co-workers (2003) have provided that these 
changes are apparent as early as 22 weeks in women who later develop 
preeclampsia. 
 
Endothelins 
These 21-amino acid peptides are potent vasoconstrictors, and 
endothelin-1 is the primary isoform produced by human endothelium. Plasma 
ET-1 levels are increased in normotensive pregnancies, but women with 
preeclampsia have even higher levels. According to Taylor and Roberts (1999), 
endothelins arise from systemic endothelial activation and not from placental 
source. 
 
Angiogenic and Antiangiogenic Proteins 
Angiogenic imbalance in preeclampsia is used to describe excessive 
amounts of antiangiogenic factors that are hypothesized to be stimulated at the 
uteroplacental interface by worsening hypoxia. Trophoblastic tissue of women 
destined to develop preeclampsia overproduces atleast two antiangiogenic 
peptides that enter the maternal circulation: 
1. Soluble Fms-like tyrosine kinase 1 (sFlt-1) 
2. Soluble endoglin (sEng)  
 
PATHOPHYSIOLOGY 
Placenta - Placentae from preeclamptic pregnancies have shown an increased 
incidence of infarcts, haematomas, congested chorionic villi, proliferative 
endarteritis and degeneration, although the changes are not specific to 
preeclampsia. Microscopy reveals increased syncitial knots, cytotrophoblastic 
cellular proliferation, fibrinoid necrosis, endothelial proliferation and calcified 
and hyalinised villous spots. 
 
Kidney – Preeclampsia appears to have a characteristic renal lesion termed as 
‘glomerular capillary endotheliosis’. The glomeruli are diffusely enlarged and 
avascular. Electron microscopy reveals endothelial cell hyperplasia and 
exudation of foamy macrophages, lymphocytes and polymorphonuclear 
leukocytes within the capillary lumen and mesangium. The capillary walls 
show hypertrophied endothelial cells, subendothelial fibrinoid and granular 
deposits and interposition of mesangial cells resulting in reduced glomerular 
filtration. However, these lesions resolve completely after pregnancy. 
 
Liver – The pathological changes in the liver include periportal haemorrhages, 
ischaemic lesions and fibrin deposition. Liver damage may vary from mild 
hepatocellular necrosis to severe lung injury with marked increase in liver 
enzymes, subcapsular rupture and rarely even liver rupture. 
 
Brain – The brain may show cortical and subcortical petechial hemorrhages, 
subcortical oedema, multiple areas of softening throughout the brain and gross 
intracerebral haemorrhage in the basal ganglia or pons, often with rupture into 
the ventricles. The classical microscopic lesions consist of fibrinoid necrosis of 
the arterial wall and perivascular microinfarcts and haemorrhages. 
 
Other organs – Subendocardial petechial haemorrhages may be present in the 
myocardium. The lungs may demonstrate pulmonary oedema. Haemorrhages 
and necrosis of the adrenal glands are likely to occur. 
COMPLICATIONS 
Maternal 
1. Eclampsia 
2. HELLP syndrome 
3. Abruption placenta 
4. Acute left ventricular failure with pulmonary oedema 
5. Acute renal failure 
6. Cerebrovascular accidents 
Fetal 
1. Intrauterine death 
2. Intrauterine growth restriction 
3. Prematurity 
4. Antepartum and intrapartum asphyxia 
 
MANAGEMENT 
The only definitive cure of preeclampsia is termination of pregnancy. 
Hence, management is directed towards early detection and amelioration of its 
progression, the goal being to prolong the pregnancy to achieve fetal maturity 
and prevent maternal complications. Management is determined by the period 
of gestation and the maturity and growth of the foetus. If the pregnancy is 37 
weeks or more, elective induction of labour should be performed. When 
hypertension develops earlier, the aim is to continue pregnancy upto 37 weeks 
if possible, with close maternal and fetal monitoring to ensure adequate growth 
and maturity of the baby. 
The management of severe preeclampsia at various gestational ages is as 
follows: 
<=24 weeks -     stabilize the patient and terminate pregnancy 
25 – 33 weeks                    -   expectant management with intensive 
maternal and fetal surveillance. Deliver if 
maternal or fetal indication  
>= 34 weeks                     -        stabilize the patient, strict fetal surveillance and 
deliver 
Antihypertensive therapy plays a very important role in preeclampsia. 
Antihypertensive agents reduce the blood pressure and thereby allow 
continuation of pregnancy and reduce the need to terminate the pregnancy 
prematurely. The commonly used antihypertensives include 
Methyldopa: 
Methyldopa is a centrally acting agent (alpha-adrenergic receptor 
blocker) and remains the drug of first choice for treating hypertension in 
pregnancy. It has been the most frequently assessed antihypertensive in 
randomized trial and has the longest safety track record. Treatment does not 
seem to have adverse effects on utero-placental or on foetal haemodynamics. 
Long term use has not been associated with fetal or neonatal problems and 
there are safety data for children exposed in utero up to 7.5 years follow up 
available, the children exhibited intelligence and cognitive development similar 
to control subjects. Dose of methyldopa is 250 mg (thrice or four times daily), 
not exceeding 3 gm/day. Side effects are consequence of central alpha-2 
agonism or decrease peripheral sympathetic tone and include decreased mental 
alertness and impaired sleep leading to fatigue and depression in some patients, 
increased liver enzymes (in 5% cases) and a positive coomb’s test (rare). 
 
Labetalol: 
Labetalol is an adrenergic receptor blocking agent possessing both 
alpha-1 (Post synaptic) and beta receptor blocking activity (4 times more potent 
action on beta-receptors than on alpha receptors). It lowers blood pressure by 
partially blocking alpha-adrenoceptors in the peripheral arterioles, thus causing 
vasodilatation and resulting reduction of peripheral resistance. At the same 
time, blocking of beta-adrenoceptors in the myocardium prevents reflex 
tachycardia and subsequent elevation of blood pressure. Recommended initial 
dose 100 mg twice daily, maximum dose is 2,400 mg daily. The peak effects of 
single oral doses of labetalol occur within 2 to 4 hours. The duration of effect 
depends upon dose, lasting at least 8 hours following single oral doses of 100 
mg and more than 12 hours following single oral doses of 300 mg. The 
maximum, steady-state blood pressure response upon oral, twice-a-day dosing 
occurs within 24 to 72 hours. The metabolism of labetalol is mainly through 
conjugation to glucuronide metabolites. These metabolites are present in 
plasma and are excreted in the urine, and via the bile, into the faeces. Adverse 
effects are consequence of alpha receptor block and include fatigue, lethargy, 
and exercise intolerance due to alpha 2 blocking effect in skeletal muscle 
vasculature, peripheral vasoconstriction, sleep disturbances, and bronchospasm. 
Labetalol should not be used in women with asthma or having history of 
obstructive airway diseases, uncontrolled CCF, 2nd or 3rd degree AV block, 
severe peripheral arterial disease and hepatic impairment.  
 
Nifedipine: 
Nifedipine is a calcium channel blocker, used in preeclampsia as first-
line therapy or in combination with other antihypertensives. Nifedipine is 
available as 5 mg and 10 mg tablets. The dose is 10-20 mg three or four times 
daily, with a maximum dose of 120 mg/ day. 
 
Hydralazine: 
Hydralazine acts directly on the arterial smooth muscle to cause 
vasodilatation. It is given orally in a dose of 25 to 100 mg three or four times 
daily with a maximum daily dose 300 mg. 
 
 
 
    
 
 
 
  
 
 
 
 
AIM OF THE STUDY 
This study compares the efficacy of oral Labetalol versus oral Alpha 
methyl dopa in the management of Pre Eclampsia in terms of reducing the 
blood pressure, need for labour induction, mean birth weight, APGAR score 
and rate of neonatal admissions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
 
STUDY DESIGN:  
Prospective case control study 
 
SETTINGS: 
This randomized prospective comparative study was conducted at 
Institute of Social Obstetrics and Govt. Kasturba Gandhi Hospital for Women 
and Children, Triplicane, Chennai, on hundred patients, diagnosed as 
preeclampsia and admitted in the Eclampsia ward. 
 
DURATION OF STUDY: 
From September 2010 to August 2011 
 
METHODOLOGY: 
The patients included in this study were assigned to two groups at 
random of 50 patients in each group. 
 
GROUP 1: 
Tablet Alpha methyl dopa (Aldomet) 250 mg was given thrice daily. 
GROUP 2: 
Tablet Labetalol 100 mg was given twice daily.              
 
 INCLUSION CRITERIA 
All patients with Gestational Hypertension (more than 20 weeks of gestation 
till term)    
•  Systolic Blood Pressure of 140 mm of Hg or more 
• Diastolic Blood Pressure of 90 mm of Hg or more 
• Proteinuria ( 0.3 g in 24 hours or more/ 1+ dipstick or more)  
 
EXCLUSION CRITERIA 
• Chronic Hypertension 
• Renal Disease 
• Liver Disease 
• Bronchial Asthma 
• GDM 
• Cardiac Disease 
• Imminent symptoms : 
 Headache  
 Blurring  
 Epigastric pain 
 Oliguria(<500 mg/24 hrs) 
 
 
 
 • Complications –  
 Acute LVF  
 Coagulation failure 
 Intracerebral Hemorrhage 
 HELLP Syndrome 
• Eclampsia  
 
PROCEDURE  
                    Informed consent was obtained from these patients before 
administration of the drugs. Blood Pressure was recorded every 12th hourly. 
The treatment was continued till delivery if the blood pressure is controlled. If 
the blood pressure was not controlled within 48 hours, the dose of drugs was 
doubled. Blood pressure was measured by a mercury sphygmomanometer over 
the right arm in the sitting position after a period of rest for 15 minutes. 
Korotkoff phase 5 was used to define diastolic blood pressure. Proteinuria was 
detected using the sulphasalicylic acid test. The period of study was 1 year. The 
change in BP after 48 hours, need for induction, and mode of termination of 
pregnancy, birth weight, Apgar score and neonatal admissions were recorded. 
 
 
 
 
RESULTS AND ANALYSIS 
This study was commenced with 100 women and the outcome was 
analyzed using various parameters. The results were subjected to statistical 
analysis using the t test and chi square test. 
AGE GROUP: 
    TABLE 1: 
The above table shows the prevalence of preeclampsia in each age group.   
Most of the patients in both Groups were in the age group of 21-25 yrs. 
42% of cases in Group 1 and 38% of cases in Group 2 were in the age group of 
21-25 yrs. However, this was not statistically significant (p value = 0.933) 
  
 
 
 
 
 
 
AGE 
 IN 
YEARS 
LEGEND  GROUP 1 
ALPHA METHYL 
DOPA 
GROUP 2 
LABETALOL 
Total 
< 20 1 Count 6 6 12 
% within 
GROUP 
12.0% 12.0% 12.0% 
21-25 2 Count 21 19 40 
% within 
GROUP 
42.0% 38.0% 40.0% 
26-30 3 Count 17 20 37 
% within 
GROUP 
34.0% 40.0% 37.0% 
>30 4 Count 6 5 11 
% within 
GROUP 
12.0% 10.0% 11.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
  
 
 
 
 
 
 
 
           .  
 
 
 
 
 
 
 
 
 
 
 
 
 
 TABLE 2: 
 GROUP N Mean Std. Deviation Std. Error Mean 
AGE (IN YRS) 1 50 25.50 3.808 .539 
2 50 25.82 4.443 .628 
The above table shows the mean ages of the patients in both the Groups. 
The difference between the mean ages between the two Groups is not 
statistically significant (p value = 0.700). 
 
PARITY: 
TABLE 3: 
PARITY LEGEND  GROUP 1  
ALPHA METHYL 
DOPA 
GROUP 2 
LABETALOL 
Total 
PRIMI 1 Count 30 21 51 
% within 
GROUP 
60.0% 42.0% 51.0% 
MULTI 2 Count 20 29 49 
% within 
GROUP 
40.0% 58.0% 49.0% 
 Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
p value = 0.072 
60% of women in Group 1 and 40% of women in Group 2 were primigravidae. 
40% of women in Group 1 and 58% of women in Group 2 were multigravidae. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
GESTATIONAL AGE: 
          TABLE 4: 
 GROUP N Mean Std. 
Deviation 
Std. Error 
Mean 
GESTATION AGE (IN 
WEEKS) 
1 50 37.90 1.930 .273 
2 50 37.94 1.596 .226 
 
The above table shows the mean gestational age in both the Groups. The 
difference between the mean gestational ages between the two Groups is not 
statistically significant (p value = 0.910). 
 
 
BODY MASS INDEX: 
TABLE 5: 
 GROUP N Mean Std. Deviation Std. Error Mean 
BODY MASS 
INDEX 
1 50 27.0076 3.28910 .46515 
2 50 27.3086 3.76136 .53194 
 
The above table shows the mean BMI in both the Groups. The 
difference between the mean BMI between the two groups is not significant (p 
value = 0.671). 
 
 
 
 
 
 
  
 
 
 
 
 
 
BLOOD PRESSURE: 
    
TABLE 6: 
 GROU
P 
N Mean Std. Deviation Std. Error Mean 
SYSTOLIC BLOOD 
PRESSURE IN MM OF HG 
1 50 150.60 8.668 1.226 
2 50 150.20 8.204 1.160 
DIASTOLIC BLOOD 
PRESSURE IN MM OF HG 
1 50 103.40 4.785 .677 
2 50 102.40 4.314 .610 
 
The above table shows the mean systolic and diastolic blood pressures 
in both the Groups. There is no statistically significant difference between the 
mean systolic blood pressures between the two Groups (p value = 0.813). Also 
there is no statistically significant difference between the mean diastolic blood 
pressures between the two Groups (p value =0.275)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
BP AFTER 48 HOURS: 
 
TABLE 7: 
BP AFTER 48 HRS GROUP N Mean Std. Deviation Std. Error Mean 
SYSTOLIC BLOOD 
PRESSURE IN MM OF HG 
1 50 146.20 8.303 1.174 
2 50 144.60 8.621 1.219 
DIASTOLIC BLOOD 
PRESSURE IN MM OF HG 
1 50 95.00 7.354 1.040 
2 50 91.20 6.273 .887 
 
The above table shows the mean systolic and diastolic blood pressures 
in both the Groups 48 hrs after administration of the drug. There is no 
statistically significant difference between the mean systolic blood pressures 
between the two Groups (p value = 0.347). However, there is a statistically 
significant difference between the mean diastolic blood pressures between the 
two Groups (p value =0.007)  
 
 
 
 
 
 
 
  
 
 
 
NEED TO INCREASE THE DOSE: 
 
TABLE 8: 
 
This table shows the need to increase the dose after 48 hrs in both 
the groups. 36% of the cases in Group 1 needed an increase in the dose 
when compared to 18% in Group 2. There is a statistically significant 
need to increase the dose after 48 hrs in Group 1 when compared to 
Group 2 (p value = 0.043). 
 
 
 
 
 
 
 
 
 
 
 
 
NEED TO INCREASE THE 
DOSE 
 
GROUP 1 
ALPHA METHYL DOPA 
GROUP 2 
LABETALOL 
 
  
Total 
NO Count 32 41 73 
% within 
GROUP 
64.0% 82.0% 73.0% 
YES Count 18 9 27 
% within 
GROUP 
36.0% 18.0% 27.0% 
Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
NEED FOR INDUCTION: 
 
TABLE 9: 
 
INDUCTION 
 
GROUP 1 
ALPHA METHYL DOPA 
GROUP 2 
LABETALOL 
Total 
  
NIL Count 43 41 84 
% within GROUP 86.0% 82.0% 84.0% 
PGE2 GEL Count 7 9 16 
% within GROUP 14.0% 18.0% 16.0% 
Total Count 50 50 100 
% within GROUP 100.0% 100.0% 100.0% 
 
The above table shows the need for induction in both the Groups. 14% 
in Group 1 and 18% in Group 2 were induced with PGE2 gel. However, this is 
not statistically significant (0.585) 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
MODE OF DELIVERY: 
 
TABLE 10: 
 
p value = 0.750 
The above table shows the mode of delivery in both the Groups. 44% of 
cases in Group 1 and 40% of cases in Group 2 underwent Emergency LSCS. 
36% of cases in Group 1 and 34% of cases in Group 2 were delivered by 
Labour natural. 
 
 
 
 
 
 
 
MODE OF DELIVERY 
 
GROUP 1 
ALPHA METHYL DOPA 
 Total 
  
GROUP 2 
LABETALOL 
 
ELECTIVE LSCS Count 2 2 4 
% within GROUP 4.0% 4.0% 4.0% 
ELECTIVE RPT LSCS Count 1 4 5 
% within GROUP 2.0% 8.0% 5.0% 
EMERGENCY LSCS Count 22 20 42 
% within GROUP 44.0% 40.0% 42.0% 
EMERGENCY RPT LSCS Count 7 7 14 
% within GROUP 14.0% 14.0% 14.0% 
LABOUR NATURAL Count 18 17 35 
% within GROUP 36.0% 34.0% 35.0% 
Total Count 50 50 100 
% within GROUP 100.0% 100.0% 100.0% 
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BP AT THE TIME OF DELIVERY: 
 
TABLE 11: 
BP AT THE TIME OF 
DELIVERY 
GROU
P 
N Mean Std. Deviation Std. Error 
Mean 
SYSTOLIC BP IN MM OF 
HG 
1 50 143.00 9.530 1.348 
2 50 139.40 9.982 1.412 
DIASTOLIC BP IN MM OF 
HG 
1 50 91.60 7.918 1.120 
2 50 89.40 6.197 .876 
 
 
The above table shows the mean systolic and diastolic blood pressures 
in both the Groups at the time of delivery. There is no statistically significant 
difference between the mean systolic blood pressures between the two Groups 
(p value = 0.068). Also there is no statistically significant difference between 
the mean diastolic blood pressures between the two Groups (p value =0.125)
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
BIRTH WEIGHT: 
TABLE 12: 
 GROUP N Mean Std. Deviation Std. Error Mean 
BIRTH WEIGHT 1 50 2.67736 .604872 .085542 
2 50 3.11936 .611578 .086490 
 
The above table shows the mean birth weight in both the Groups. The 
difference between the mean birth weights between the two groups is 442 g, 
which is statistically significant (p value = 0.000 < 0.01). 
 
 
 
APGAR: 
TABLE 13: 
 GROUP N Mean Std. Deviation Std. Error Mean 
APGAR 1 50 8.24 1.318 .186 
2 50 8.64 1.064 .151 
 
The above table shows the mean APGAR scores in both the Groups. 
The difference between the mean APGAR score between two groups is 0.4, 
which is not statistically significant (p value = 0.090) 
 
 
 
 
 
 
  
 
 
 
 
 
NICU ADMISSION: 
 
TABLE 14: 
 
 
  
 
 
 
 
 
 
 
 
The above table shows the need for NICU admission in both the Groups. 
10% of babies delivered in Group 1 and 4% of babies delivered in Group 
2 needed NICU admission. However, this difference is not statistically 
significant (p value = 0.240).  
 
 
  
 
NICU 
ADMISSION 
 GROUP 1 
ALPHA METHYL DOPA 
GROUP 2 
LABETALOL 
TOTAL 
    
NO Count 45 48 93 
% within 
GROUP 
90.0% 96.0% 93.0% 
% of Total 45.0% 48.0% 93.0% 
YES Count 5 2 7 
% within 
GROUP 
10.0% 4.0% 7.0% 
% of Total 5.0% 2.0% 7.0% 
Total Count 50 50 100 
% within 
GROUP 
100.0% 100.0% 100.0% 
% of Total 50.0% 50.0% 100.0% 
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DISCUSSION 
 
This randomized prospective study compares the efficacy of oral 
labetalol versus oral alpha methyl dopa in the management of preeclampsia. 
Preeclampsia is an important cause of maternal mortality and perinatal 
mortality and morbidity. Oral antihypertensive drugs have played a major role 
in controlling the disease progression, preventing Eclampsia and other dreaded 
complications, prolonging pregnancy, and reducing fetal pre maturity. 
Though methyl dopa has been used routinely because of its safety 
profile, several controlled trials have suggested labetalol to be a better drug in 
controlling hypertension with the least side effects. 
A prospective study was carried out at City Hospital, Nottingham, UK 
in 1979. Nineteen patients with Pregnancy Induced Hypertension whose Mean 
arterial pressure were >103.3 mm of Hg were selected. They were randomly 
allocated to two groups. They were given either Labetalol 400 mg or Alpha 
methyl dopa 750 mg daily. This dose was doubled 3 days later if satisfactory 
BP control had not occurred. Significant falls in BP only occurred in the group 
treated with labetalol, and daily BP control was better in this group. There was 
a higher incidence of spontaneous labour in the labetalol group and a 
significant difference in the Bishop score of the cervix between the two groups. 
There were no apparent detrimental effects on the foetus antenatally, during 
labour or postpartum.  
In our study, the initial daily dose of labetalol was 200 mg and the initial 
daily dose of alpha methyl dopa was 750 mg. The dose was increased after 48 
hrs if satisfactory BP control had not occurred. Statistically significant fall 
occurred only in the diastolic blood pressure in the labetalol group after 48 hrs 
(p = 0.007). There was no statistically significant difference between the need 
for PGE2 induction between alpha methyl dopa and labetalol groups. 86% of 
cases in alpha methyl dopa group and 82% of cases in labetalol group went in 
for spontaneous labour. Only 5% of babies born in alpha methyl dopa group 
and 2% of babies born in labetalol group required NICU admission. This 
difference was also not statistically significant (p value = 0.240) 
A prospective study (2005) was carried out at Al-Jahra Hospital, Jahra, 
Kuwait to assess the efficacy and safety of labetalol compared with methyldopa 
in the management of mild and moderate cases of pregnancy-induced 
hypertension (PIH). One hundred four primigravidae with PIH were randomly 
allocated to receive either labetalol (group A) or methyldopa (group B). The 
dose of the drugs was doubled every 48 h to maintain a mean arterial blood 
pressure ≤103.6 mmHg. Ten patients in group B (18.5%) developed significant 
proteinuria whereas none developed proteinuria in group A. Labetalol was 
quicker and more efficient at controlling blood pressure, having a beneficial 
effect on renal functions and causing fewer side effects compared with 
methyldopa. The rate of induction of labor and rate of caesarean section for 
uncontrolled PIH was less in group A (48% and 1%, respectively) compared 
with group B (63.0% and 5.6%, respectively). Moreover a higher Bishop score 
at induction of labor was noticed in group A. Conclusions: Labetalol is better 
tolerated than methyldopa, gives more efficient control of blood pressure, and 
may have a ripening effect on the uterine cervix. 
In our study, 44% of cases in alpha methyl dopa group and 40% of cases 
in labetalol group delivered by Emergency LSCS; 36% of cases in alpha 
methyl dopa group and 34% of cases in labetalol group delivered by Labour 
Natural. 
In a Randomized controlled trial (1988), labetalol was compared with 
methyldopa in a randomized controlled trial involving 176 pregnant women 
with mild to moderate hypertension. Diastolic blood pressure below 86 mmHg 
was obtained in a similar proportion of women given labetalol or methyldopa. 
Intrauterine death occurred in four women treated with methyldopa, and the 
one neonatal death on day 1 occurred in the labetalol group. The average birth 
weight and the proportion of preterm or small-for-gestational-age babies were 
similar in both groups. Heart rate, blood pressure, blood glucose, respiratory 
rate, and Silverman score of the babies did not differ between the two treatment 
groups, whether the comparison was made for all the infants or only for those 
that were preterm or small-for-gestational-age. These data indicate that 
maternal beta blockade with labetalol is as safe as methyldopa for the fetus and 
the newborn. 
In our study, there were no reports of intrauterine deaths. There was a 
statistically significant increase in the mean birth weight in the labetalol group 
when compared to alpha methyl dopa group (3.11 kg and 2.67 kg respectively, 
p value = 0.00) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
• This is a study comparing the efficacy of oral Labetalol and Alpha 
methyl dopa in the management of preeclampsia, carried out in ISO 
KGH. 
• The time duration of the study was from September 2010 to August   
2011. 
• 100 patients diagnosed as preeclampsia and admitted to ISO KGH were 
included in this study.  
• Inclusion criteria included those who came under the definition of 
preeclampsia.  
• Exclusion criteria included those who had pre-existing medical 
disorders, those who had features of imminent Eclampsia, Eclampsia 
and those who developed complications of preeclampsia like acute left 
ventricular failure and HELLP syndrome.  
• These 100 patients were assigned to two groups at random of 50 patients 
in each group. Group 1 was started on tablet Alpha methyl dopa 250 mg 
thrice daily and Group 2 was started on tablet Labetalol 100 mg twice 
daily. Blood Pressure and proteinuria was recorded every 12th hourly.  
• The treatment was continued till delivery if the blood pressure is 
controlled. If the blood pressure was not controlled within 48 hours, the 
dose of drugs was doubled. 
• The relationship of age, parity, gestational age and body mass index to 
prevalence of preeclampsia in both the groups has been analyzed. Also 
the fall in BP after 48 hrs, need to increase the dose of the drugs, need 
for labour induction, method of delivery, blood pressure at the time of 
delivery, birth weight, APGAR score and neonatal admissions in each 
group has been analyzed.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
• This is a study comparing the efficacy of Labetalol and Alpha methyl 
dopa in the management of preeclampsia, in which 50 patients were 
started on oral Labetalol and 50 patients were started on oral Alpha 
methyl dopa. 
• Significant fall in the diastolic blood pressure after 48 hrs occurred only 
in the labetalol group (p = 0.007).   
• In the Alpha methyl dopa group, there was a significant need to increase 
the dose of the drug after 48 hrs (p = 0.043) 
• There appears to be no significant difference in the rate of induction 
between the two groups (p =0.585) 
• The mean birth weight was significantly higher (p = 0.00) in the 
labetalol group (3.11 kg) compared to the alpha methyl dopa group 
(2.67 kg).  
• There was no significant difference in the APGAR scores (p = 0.090) 
and rate of neonatal admissions (p =0.240) in both the groups. 
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 PROFORMA 
 
NAME: 
AGE: 
IP NO: 
ADDRESS: 
OBSTETRIC SCORE: 
GESTATION AGE: 
HEIGHT: 
WEIGHT: 
BODY MASS INDEX: 
BLOOD PRESSURE AT THE TIME OF ADMISSION: 
URINE ALBUMIN AT THE TIME OF ADMISSION: 
DRUG ADMINISTERED:  Alpha methyl dopa / Labetalol 
BLOOD PRESSURE AFTER 48 HRS: 
URINE ALBUMIN AFTER 48 HRS: 
NEED TO INCREASE THE DOSE:  Yes / No 
INDUCTION WITH PGE2 GEL:  Yes / No 
 
 
MODE OF DELIVERY:   
1. Elective LSCS 
2. Elective Repeat LSCS 
3. Emergency LSCS 
4. Emergency Repeat LSCS 
5. Labour Natural  
BP AT THE TIME OF DELIVERY: 
URINE ALBUMIN AT THE TIME OF DELIVERY: 
BIRTH WEIGHT: 
APGAR SCORE: 
NICU ADMISSION: Yes / No 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Master Chart
S.N
O 
G
R
O
U
P 
NAME 
AG
E 
(IN 
YR
S) 
OBSTETR
IC SCORE 
GES
TATI
ON 
AGE 
(IN 
WEE
KS) 
HEIGHT 
(IN CM) 
WEI
GH
T 
(IN 
KG) 
BODY 
MASS 
INDEX 
BLOOD 
PRESSUR
E (IN MM 
OF HG) 
URIN
E 
ALB
UMIN 
DRUG GIVEN 
BP 
AFTER 
48 HRS 
URINE 
ALBU
MIN 
AFTER 
48 
HRS 
NEED TO 
INCREAS
E THE 
DOSE 
INDUCTI
ON 
BP AT 
THE TIME 
OF 
DELIVER
Y 
URIN
E 
ALB
UMIN 
AT 
DELI
VERY 
MODE OF DELIVERY BIRTH WEIGHT 
APG
AR NICU 
1 1 ROSEMARY 35 G3P1L1
A1 
38 151 64 28.06 160/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO PGE2 
GEL 
140/90 NIL LABOUR NATURAL 2.92 9 NO 
2 1 RAJESWARI 24 PRIMI 37 148 62 28.3 150/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 140/80 NIL EMERGENCY LSCS 2.25 9 NO 
3 1 SATYA 27 G2P1L1 36 166 58 21.04 160/110 3+ ALPHA 
METHYL 
DOPA 
150/11
0 
1+ YES NIL 150/100 NIL LABOUR NATURAL 2 6 YES 
4 1 SARASWATHY 24 PRIMI 38 149 70 31.53 160/100 1+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 150/90 NIL EMERGENCY LSCS 3.25 8 NO 
5 1 KALPANA 28 PRIMI 39 144 80 38.58 140/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 140/90 NIL LABOUR NATURAL 2.92 9 NO 
6 1 DEVI 29 G2P1L1 40 148 71 32.41 150/100 1+ ALPHA 
METHYL 
DOPA 
140/10
0 
NIL YES NIL 130/80 NIL LABOUR NATURAL 2.1 9 NO 
7 1 SARASWATHY 26 PRIMI 37 156 75 30.81 150/110 2+ ALPHA 
METHYL 
DOPA 
160/10
0 
2+ YES NIL 160/110 1+ EMERGENCY LSCS 2.56 9 NO 
8 1 BHUVANESHWAR
I 
28 PRIMI 38 151 60 26.31 140/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 130/90 NIL LABOUR NATURAL 2.025 7 NO 
9 1 ANURADHA 20 PRIMI 39 150 54 24 160/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 140/80 NIL LABOUR NATURAL 2.39 8 NO 
10 1 UMA 
MAHESHWARI 
29 G2P1L1 38 157 58 23.53 160/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 150/90 NIL ELECTIVE RPT LSCS 3.135 8 NO 
11 1 JENITHA 21 PRIMI 38 149 53 23.87 150/110 2+ ALPHA 
METHYL 
DOPA 
150/10
0 
1+ YES NIL 150/100 NIL EMERGENCY LSCS 3.24 8 NO 
12 1 DEVAKI 32 G3A2 38 152 69 29.86 140/100 1+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 150/90 NIL ELECTIVE LSCS 2.53 9 NO 
13 1 HAJIRA 27 PRIMI 37 166 80 29.03 150/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 120/80 NIL EMERGENCY LSCS 2.31 9 NO 
14 1 AARIFA 22 PRIMI 36 159 70 27.68 160/110 3+ ALPHA 
METHYL 
DOPA 
150/10
0 
1+ YES PGE2 
GEL 
150/100 NIL LABOUR NATURAL 2 9 NO 
15 1 NISHANTHI 23 PRIMI 39 142 56 27.77 140/100 2+ ALPHA 
METHYL 
DOPA 
130/90 NIL NO NIL 130/90 NIL EMERGENCY LSCS 2.21 8 NO 
16 1 CHITRA 25 PRIMI 40 148 54 24.65 150/100 1+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO PGE2 
GEL 
150/80 NIL EMERGENCY LSCS 2.75 9 NO 
17 1 ANANDHI 25 PRIMI 38 149 70 31.53 150/110 2+ ALPHA 
METHYL 
DOPA 
150/11
0 
1+ YES NIL 150/100 NIL EMERGENCY LSCS 2.163 7 NO 
18 1 ZARINA BEGUM 30 G3P1L1
A1 
39 167 78 27.96 140/110 2+ ALPHA 
METHYL 
DOPA 
150/10
0 
1+ YES NIL 140/90 NIL EMERGENCY LSCS 2.81 9 NO 
19 1 NANCY  25 PRIMI 40 164 59 21.93 140/100 1+ ALPHA 
METHYL 
DOPA 
130/90 NIL NO NIL 130/90 NIL EMERGENCY LSCS 3.201 9 NO 
20 1 ROSEMATHY 20 PRIMI 39 168 60 21.25 140/110 2+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 130/90 NIL EMERGENCY  LSCS 3.332 9 NO 
21 1 VASANTHI 29 G2P1L1 39 156 60 24.65 140/100 1+ ALPHA 
METHYL 
DOPA 
140/10
0 
NIL YES NIL 140/90 NIL EMERGENCY RPT 
LSCS 
3.102 9 NO 
22 1 USAINA 24 G2P1L1 37 163 59 22.2 150/100 1+ ALPHA 
METHYL 
DOPA 
150/10
0 
NIL YES NIL 150/90 NIL EMERGENCY RPT 
LSCS 
2.81 9 NO 
23 1 SANGEETHA 26 PRIMI 37 157 60 24.34 150/110 2+ ALPHA 
METHYL 
DOPA 
150/10
0 
1+ YES NIL 150/90 NIL EMERGENCY LSCS 3.225 8 NO 
24 1 MINNALKODI 32 G3P1L1
A1 
37 158 61 24.43 160/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 150/90 NIL LABOUR NATURAL 3.615 9 NO 
25 1 RASHEELA BEE 29 G3P1L1
A1 
38 166 64 23.22 160/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 150/90 NIL EMERGENCY RPT 
LSCS 
3.402 9 NO 
26 1 SANGEETHA 23 PRIMI 40 154 68 28.67 140/100 1+ ALPHA 
METHYL 
DOPA 
130/90 NIL NO NIL 130/90 NIL LABOUR NATURAL 3.155 9 NO 
27 1 MANJULA 22 PRIMI 39 152 60 25.97 150/100 1+ ALPHA 
METHYL 
DOPA 
140/10
0 
1+ YES NIL 140/90 NIL EMERGENCY LSCS 2.275 9 NO 
28 1 INDIRAJI 25 G3A2 37 149 54 24.32 140/100 2+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 140/90 NIL ELECTIVE LSCS 2.85 9 NO 
29 1 SHAILAJA 19 PRIMI 40 141 58 29.17 140/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 140/80 NIL LABOUR NATURAL 3.075 8 NO 
30 1 MAHESWARI 32 G3P2L1 37 161 64 24.69 150/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 150/90 NIL EMERGENCY RPT 
LSCS 
2.235 9 NO 
31 1 PERIYANAYAKI 29 G2P1L0 36 160 67 26.17 150/110 2+ ALPHA 
METHYL 
DOPA 
150/11
0 
2+ YES NIL 150/110 1+ EMERGENCY LSCS 2.4 8 NO 
32 1 PREMA 23 PRIMI 40 158 69 27.64 150/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO PGE2 
GEL 
140/90 NIL EMERGENCY LSCS 2.695 9 NO 
33 1 NANDHINI 20 PRIMI 32 162 68 25.91 150/110 2+ ALPHA 
METHYL 
DOPA 
160/11
0 
2+ YES NIL 150/110 3+ LABOUR NATURAL 0.89 4 YES 
34 1 CHITRA 20 PRIMI 38 163 77 28.98 160/110 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 150/90 NIL LABOUR NATURAL 2.968 9 NO 
35 1 PRINCY 28 G2P1L1 39 166 62 22.5 170/110 3+ ALPHA 
METHYL 
DOPA 
160/11
0 
4+ YES NIL 160/100 3+ EMERGENCY LSCS 1.67 5 YES 
36 1 HEMALATHA 26 G2P1L1 37 165 74 27.18 160/110 3+ ALPHA 
METHYL 
DOPA 
160/10
0 
3+ YES NIL 150/100 1+ LABOUR NATURAL 2.651 9 NO 
37 1 MOHANA 24 PRIMI 40 154 66 27.83 140/100 1+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 120/80 NIL LABOUR NATURAL 2.84 9 NO 
38 1 MUMTAZ 31 G2P1L1 38 161 68 26.23 150/110 2+ ALPHA 
METHYL 
DOPA 
150/11
0 
1+ YES NIL 150/100 NIL EMERGENCY RPT 
LSCS 
3.35 9 NO 
39 1 DHANALAKSHMI 28 G2P1L1 39 156 64 26.3 150/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 140/90 NIL EMERGENCY RPT 
LSCS 
2.963 9 NO 
40 1 SHARMILA 23 PRIMI 39 149 62 27.93 160/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO PGE2 
GEL 
140/90 NIL EMERGENCY LSCS 3.562 9 NO 
41 1 KAVITHA 24 PRIMI 40 148 66 30.13 150/100 2+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 140/90 NIL LABOUR NATURAL 2.969 8 NO 
42 1 GAYATHRI 26 PRIMI 38 150 57 25.33 150/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 150/90 NIL EMERGENCY LSCS 2.659 9 NO 
43 1 SHAHINA 20 PRIMI 38 146 56 26.27 150/100 1+ ALPHA 
METHYL 
DOPA 
140/90 NIL NO NIL 140/90 NIL LABOUR NATURAL 2.106 8 NO 
44 1 PRIYA 25 PRIMI 39 160 72 28.13 140/100 1+ ALPHA 
METHYL 
DOPA 
130/90 NIL NO NIL 130/90 NIL EMERGENCY LSCS 2.352 7 NO 
45 1 VIJAYALAKSHMI 31 G2P1L1 38 155 66 27.47 150/100 1+ ALPHA 
METHYL 
DOPA 
150/10
0 
1+ YES NIL 150/100 NIL EMERGENCY RPT 
LSCS 
3.265 8         
NO 
46 1 HEMAVATHY 22 PRIMI 34 149 70 31.53 170/110 3+ ALPHA 
METHYL 
DOPA 
160/90 NIL NO PGE2 
GEL 
160/90 NIL EMERGENCY LSCS 1.986 5 YES 
47 1 KARPAGAM 25 G2P1L1 39 165 84 30.85 150/110 3+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 140/90 NIL EMERGENCY LSCS 3.456 9 NO 
48 1 SAIBUNISHA 26 G3P2L1 30 152 60 25.97 170/110 3+ ALPHA 
METHYL 
DOPA 
160/11
0 
3+ YES PGE2 
GEL 
150/110 4+ LABOUR NATURAL 0.98 4 YES 
49 1 SUMATHY 22 PRIMI   149 65 29.28 150/100 2+ ALPHA 
METHYL 
DOPA 
150/90 NIL NO NIL 140/90 NIL EMERGGENCY 
LSCS 
3.111 9 NO 
50 1 KAMATCHI 21 PRIMI 39 154 64 26.99 140/100 1+ ALPHA 
METHYL 
DOPA 
130/90 NIL NO NIL 130/80 NIL LABOUR NATURAL 3.155 9 NO 
51 2 SUMATHY 28 PRIMI 37 154 88 37.1 150/100 1+ LABETALOL 150/10
0 
1+ YES NIL 140/90 NIL ELECTIVE LSCS 2.21 9 NO 
52 2 MANJULA 33 G3A2 37 160 56 21.87 150/100 1+ LABETALOL 150/90 NIL NO NIL 150/90 NIL ELECTIVE LSCS 3.5 9 NO 
53 2 SHANTHI 32 G2P1L0 38 155 53 22.06 140/100 2+ LABETALOL 140/90 NIL NO NIL 130/80 NIL EMERGENCY LSCS 2.85 9 NO 
54 2 BEULA 28 G2P1L1 30 155 62 25.8 160/110 4+ LABETALOL 160/10
0 
4+ YES PGE2 
GEL 
160/100 3+ LABOUR NATURAL 1.214 3 YES 
55 2 VENNILA 27 G2P1L1 38 158 69 27.63 140/100 1+ LABETALOL 130/90 NIL NO NIL 130/90 NIL LABOUR NATURAL 2.85 9 NO 
56 2 JAMEELA BANU 22 G2P1L1 38 166 63 22.86 150/100 2+ LABETALOL 150/90 NIL NO NIL 150/90 NIL ELECTIVE RPT LSCS 2.8 9 NO 
57 2 VIJAYALAXMI 26 PRIMI 40 160 80 31.25 140/100 1+ LABETALOL 130/80 NIL NO PGE2 
GEL 
130/80 NIL EMERGENCY LSCS 2.79 9 NO 
58 2 AMMU 24 PRIMI 38 156 70 28.76 150/100 1+ LABETALOL 140/90 NIL NO PGE2 
GEL 
140/90 NIL LABOUR NATURAL 2.355 9 NO 
59 2 JOTHI 36 G2P1L1 38 157 65 26.37 150/100 1+ LABETALOL 140/90 NIL NO NIL 140/90 NIL LABOUR NATURAL 3.13 9 NO 
60 2 THENMOZHI 29 PRIMI 39 147 84 38.87 150/100 1+ LABETALOL 140/90 NIL NO PGE2 
GEL 
130/90 NIL EMERGENCY LSCS 3 9 NO 
61 2 VARALAXMI 26 PRIMI 37 154 78 32.88 140/100 1+ LABETALOL 130/80 NIL NO NIL 120/80 NIL LABOUR NATURAL 2.305 8 NO 
62 2 MADHUMITHA 22 PRIMI 38 142 60 29.75 140/110 2+ LABETALOL 140/90 NIL NO NIL 140/90 NIL EMERGENCY LSCS 4.07 8 NO 
63 2 NEELAVATHY 24 G2A1 39 153 66 28.19 160/100 2+ LABETALOL 150/90 NIL NO NIL 140/90 NIL EMERGENCY LSCS 3.7 9 NO 
64 2 DHANALAXMI 20 PRIMI 37 155 63 26.22 150/100 1+ LABETALOL 150/90 NIL NO NIL 140/90 NIL EMERGENCY LSCS 2.523 9 NO 
65 2 DEVI 29 G2P1L1 38 160 89 34.76 150/100 1+ LABETALOL 150/90 NIL NO NIL 120/80 NIL LABOUR NATURAL 3.325 9 NO 
66 2 KAMATCHI 29 G3P2L1 37 148 54 24.65 150/110 2+ LABETALOL 150/10
0 
2+ YES PGE2 
GEL 
140/100 1+ EMERGENCY LSCS 3.75 9 NO 
67 2 SAMUNDESHWAR
I 
19 PRIMI 38 155 55 22.89 140/100 1+ LABETALOL 140/90 NIL NO NIL 120/80 NIL EMERGENCY LSCS 3.78 9 NO 
68 2 INDARANI 26 G2P1L1 38 163 59 22.2 150/100 1+ LABETALOL 140/80 NIL NO NIL 140/80 NIL EMERGENCY RPT 
LSCS 
3.05 7 NO 
69 2 PITCHAIAMMAL 22 G2P1L0 38 154 68 28.67 140/100 1+ LABETALOL 140/90 NIL NO NIL 130/90 NIL ELECTIVE RPT LSCS 4.015 9 NO 
70 2 SUMATHY 36 G3P1L1
A1 
39 153 56 23.92 150/100 1+ LABETALOL 150/10
0 
NIL YES NIL 140/90 NIL EMERGENCY RPT 
LSCS 
3.455 9 NO 
71 2 FAIZ JAHAN 28 G2P1L1 37 149 71 31.98 150/100 2+ LABETALOL 150/10
0 
1+ YES NIL 150/100 NIL EMERGENCY RPT 
LSCS 
3.37 9 NO 
72 2 KAVITHA 24 PRIMI 40 159 66 26.1 150/100 1+ LABETALOL 140/90 NIL NO NIL 140/80 NIL EMERGENCY LSCS 3.625 9 NO 
73 2 REBECCA 21 PRIMI 36 144 56 27 160/110 3+ LABETALOL 150/90 NIL NO PGE2 
GEL 
150/90 NIL LABOUR NATURAL 2.78 9 NO 
74 2 SEETHA 29 G2P1L1 38 166 66 23.99 170/110 4+ LABETALOL 160/11
0 
3+ YES PGE2 
GEL 
160/100 2+ EMERGENCY LSCS 2.955 9 NO 
75 2 BHAVANI 28 PRIMI 39 147 66 30.54 140/100 1+ LABETALOL 130/90 NIL NO NIL 120/80 NIL EMERGENCY LSCS 3.22 9 NO 
76 2 CHITRA 25 PRIMI 38 148 59 26.93 150/110 2+ LABETALOL 150/10
0 
1+ YES NIL 150/100 NIL EMERGENCY LSCS 3.19 9 NO 
77 2 VANESHREE 25 G3P1L1
A1 
38 167 68 24.38 150/110 1+ LABETALOL 140/90 NIL NO NIL 140/80 NIL ELECTIVE RPT LSCS 4.125 9 NO 
78 2 SABEERA BEGUM 22 PRIMI 40 155 66 27.47 140/100        
1+ 
LABETALOL 130/90 NIL NO PGE2 
GEL 
130/90 NIL EMERGENCY LSCS 2.955 8 NO 
79 2 NITHYAVATHI 29 G2P1L1 38 164 64 23.79 150/100 2+ LABETALOL 140/90 NIL NO NIL 140/80 NIL LABOUR NATURAL 2.69 8 NO 
80 2 SASIKALA 22 G2P1L1 39 168 78 27.63 150/110 1+ LABETALOL 150/90 NIL NO NIL 150/100 NIL LABOUR NATURAL 3.27 9 NO 
81 2 ARIFA BEE 24 G2A1 39 157 60 24.34 140/100 1+ LABETALOL 140/90 NIL NO NIL 130/90 NIL EMERGENCY LSCS 3.711 9 NO 
82 2 KOTTEESWARI 30 PRIMI 37 153 57 24.34 160/110 3+ LABETALOL 160/90 NIL NO NIL 150/90 NIL EMERGENCY LSCS 4 9 NO 
83 2 TAMILSELVI 29 G3P1L1
A1 
38 165 79 29.02 140/100 1+ LABETALOL 140/80 NIL NO NIL 140/90 NIL ELECTIVE RPT LSCS 3.25 9 NO 
84 2 SHANAZ BEGUM 18 PRIMI 39 151 59 25.88 140/100 1+ LABETALOL 130/90 NIL NO NIL 130/90 NIL LABOUR NATURAL 3.285 9 NO 
85 2 RAJESWARI 27 G2P1L1 37 151 71 31.14 160/100 1+ LABETALOL 150/90 NIL NO NIL 150/90 NIL EMERGENCY RPT 
LSCS 
2.925 9 NO 
86 2 MANIMEGALAI 36 G4P1L1
A2 
39 161 65 25.08 150/110 2+ LABETALOL 150/90 NIL NO NIL 140/90 NIL LABOUR NATURAL 3.25 8 NO 
87 2 SAINA 19 PRIMI 40 144 59 28.45 160/100 2+ LABETALOL 150/90 NIL NO NIL 140/90 NIL EMERGENCY LSCS  3.152 8 NO 
  
88 2 PRABAVATHY 24 PRIMI 37 152 73 31.6 160/100 2+ LABETALOL 150/90 NIL NO PGE2 
GEL 
150/90 NIL LABOUR NATURAL 2.97 9 NO 
89 2 ALMAS  21 PRIMI 38 160 70 27.34 160/100 2+ LABETALOL 150/90 NIL NO NIL 150/90 NIL EMERGENCY LSCS 3.845 9 NO 
90 2 KOKILA 25 PRIMI 38 155 59 24.56 160/100 2+ LABETALOL 150/90 NIL NO NIL 140/90 NIL EMERGENCY LSCS 3.2 9 NO 
91 2 MEHERNISHA 30 G2P1L1 40 162 66 25.15 140/100 1+ LABETALOL 140/90 NIL NO NIL 130/90 NIL LABOUR NATURAL 3.1 9 NO 
92 2 MAHALAKSHMI 29 G3P1L1
A1 
38 152 60 25.97 160/100 1+ LABETALOL 150/90 NIL NO NIL 140/90 NIL EMERGENCY RPT 
LSCS 
3.212 9 NO 
93 2 KALAIARASI 29 G2P1L1 39 164 65 24.17 140/100 2+ LABETALOL 140/80 NIL NO NIL 130/80 NIL LABOUR NATURAL 2.563 9 NO 
94 2 SEETHA 24 PRIMI 34 165 60 22.04 160/100 2+ LABETALOL 160/10
0 
2+ YES NIL 150/100 3+ LABOUR NATURAL 1.243 5 YES 
95 2 SAIRA BANU 19 PRIMI 39 145 58 27.59 150/100 2+ LABETALOL 140/90 NIL NO NIL 130/90 NIL EMERGENCY LSCS 2.856 9 NO 
96 2 SATYA 23 G2A1 38 153 68 29.05 140/100 1+ LABETALOL 130/90 NIL NO NIL 130/90 NIL LABOUR NATURAL 2.658 9 NO 
97 2 SHAKIRA 20 G2A1 37 150 70 31.11 160/110 3+ LABETALOL 160/11
0 
1+ YES NIL 150/100 NIL EMERGENCY RPT 
LSCS 
3.985 9 NO 
98 2 PARVATHY 26 G2P1L1   163 78 29.36 160/110 2+ LABETALOL 150/90 NIL NO NIL 140/90 NIL LABOUR NATURAL 3.252 9 NO 
99 2 UMADEVI 23 G3P1L1
A1 
39 159 64 25.32 150/100 1+ LABETALOL 140/90 NIL NO NIL 150/90 NIL EMERGENCY RPT 
LSCS 
3.673 9 NO 
100 2 RAHIMA 24 G2P1L1   154 65 27.41 160/100 2+ LABETALOL 140/90 NIL NO NIL 140/90 NIL EMERGENCY LSCS 2.986 9 NO 
